A Plus Biotechnology Co

A Plus Biotechnology Co EBITDA per Share

The EBITDA per Share of A Plus Biotechnology Co (6918.TWO) as of Oct 30, 2026 is 6.11 TWD. In the previous year, EBITDA per Share was 5.66 TWD — a change of 7.99% (higher).

EBITDA per Share

6.11TWD

YoY

7.99%

Last updated:

EBITDA per Share of A Plus Biotechnology Co is 2024 6.11 TWD. EBITDA per Share of A Plus Biotechnology Co was 2023 5.66 TWD. It decreases by 7.99% higher compared to the previous year.

The A Plus Biotechnology Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
1.46 TWD
Jan 1, 2020
1.47 TWD
Jan 1, 2021
1.64 TWD
Jan 1, 2022
2.32 TWD
Jan 1, 2023
5.66 TWD
Jan 1, 2024
6.11 TWD
The A Plus Biotechnology Co EBITDA per Share history
YEAREBITDA per ShareYoY
6.11TWD+7.99%
5.66TWD+144.16%
2.32TWD+41.17%
1.64TWD+11.30%
1.47TWD+1.15%
1.46TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

A Plus Biotechnology Co Stock analysis

What does A Plus Biotechnology Co do? A Plus Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sales of orthopedic medical equipment. The company offers trauma products such as orthopedic internal fixation bone plates, bone nails, and external fixators for stable fracture fixation. Orthopedic products include knee arthritis correction systems and hallux valgus correction systems, while spinal products feature spinal fixation systems and spinal intervertebral fusion devices. Proxy products encompass artificial bone replacement and cartilage repair solutions. The company primarily sells its products domestically in Taiwan and exports to mainland China, Asia, the United States, and Africa, serving healthcare providers and medical institutions across these regions. Trauma products are utilized for stabilizing fractures across various bone types and locations, with applications including intramedullary nails and cables. Orthopedic products assist in precise correction and fixation, such as additive manufacturing surgical guide plates. Spinal products support spinal fixation and intervertebral height maintenance through spinal intervertebral fusion devices. Proxy products like cell therapy and artificial bone replacement cater to tissue repair and regeneration needs. The company's export markets include mainland China, Asia, the United States, and Africa, with domestic sales in Taiwan forming a significant segment. The company's product portfolio includes orthopedic internal fixation bone plates, bone nails, and spinal fixation systems, which are sold to medical institutions and healthcare providers. Trauma products such as external fixators and intramedullary nails are distributed to hospitals and clinics for fracture treatment. Orthopedic products like knee arthritis correction systems are targeted at specialized surgical procedures. Spinal products including intervertebral fusion devices are used in spinal surgeries. Proxy products such as cartilage repair solutions and cell therapy are supplied to medical facilities requiring tissue regeneration treatments. A Plus Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about A Plus Biotechnology Co stock

EBITDA per Share of A Plus Biotechnology Co is 6.11 TWD in 2024.

EBITDA per Share of A Plus Biotechnology Co changed from 5.66 TWD to 6.11 TWD, representing a 7.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share A Plus Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — A Plus Biotechnology Co

All Key Metrics — A Plus Biotechnology Co